Are We Ready for Multiple Switches Between Reference Products and Biosimilars?
Fabio Vieira TEIXEIRA,
Laurent PEYRIN-BIROULET,
Silvio DANESE
Abstract:HIGHLIGHTS• The most crucial benefit of biosimilars is that they bring more significant cost reduction and increase access to advanced therapies.• For this to occur, it is imperative not only to use biosimilars in naïve patients but also to switch to biosimilars in those patients who have started therapy with reference biologics.• So far, studies have demonstrated effectiveness and safety of single switch between a reference product and a biosimilar.• The purpose of this manuscript is to discuss whether scient… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.